RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

NCT06420973 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Carcinoma
Fallopian Tube Carcinoma
Primary Peritoneal Carcinoma

Interventions

DRUG: RC48+carboplatin±bevacizumab

Sponsor

Peking University Cancer Hospital & Institute